Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
Planned sales, announced before they happen

2 trading plans running, 12 Form 144 notices for $8.2M

10-Q, 10-K and Form 144

What RGEN's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Nov 9, 2023 to Dec 15, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
Tony J. Hunt
Director and Executive Chair of the Board of Directors
Adopted 10b5-1 plan Dec 11, 2025 10-K Feb 26, 2026
Jason Garland
Chief Financial Officer
Adopted 10b5-1 plan Dec 8, 2025 10-K Feb 26, 2026
Olivier Loeillot
President and Chief Executive Officer
Adopted 10b5-1 plan Aug 19, 2025 10-Q Nov 4, 2025
Jason K. Garland
Chief Financial Officer
Adopted 10b5-1 plan Dec 13, 2024 10-K Mar 14, 2025
Olivier Loeillot
President and Chief Executive Officer
Adopted 10b5-1 plan Dec 12, 2024 10-K Mar 14, 2025
Tony J. Hunt
Director and Executive Chair of the Board of Directors
Adopted 10b5-1 plan Dec 9, 2024 10-K Mar 14, 2025
Tony J. Hunt
Chief Executive Officer
Adopted 10b5-1 plan Nov 9, 2023 10-K Feb 22, 2024

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 21 filings checked since May 2, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 5, 2026 Loeillot Olivier
Officer, Director
4,202 $798K
Oct 5, 2026 Loeillot Olivier
Officer, Director
1,333 $238K
Sep 24, 2026 Loeillot Olivier
Officer, Director
12,946 $2.5M
Sep 21, 2026 Loeillot Olivier
Officer, Director
5,426 $977K
Sep 4, 2026 Loeillot Olivier
Officer, Director
3,035 $504K
Aug 20, 2026 Loeillot Olivier
Officer, Director
5,426 $977K
Jul 16, 2026 Garland Jason K
Officer
530 $80K
Jun 25, 2026 Garland Jason K
Officer
733 $106K
Apr 21, 2026 Loeillot Olivier
Officer, Director
3,832 $536K
Dec 17, 2025 DAWES KAREN A
Director
275 $44K
Nov 25, 2025 Loeillot Olivier
Officer, Director
7,041 $1.2M
Nov 18, 2025 Bylund James
Officer
2,191 $331K
Show the other 4 notices

From the Form 144 XML filed with the SEC, since Nov 18, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.